Limitations of cellular models in Parkinson's disease research.

[1]  Ling Lin,et al.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. , 2005, Human molecular genetics.

[2]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[3]  J. Zimmer,et al.  Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP+ toxicity by GDNF , 2005, The European journal of neuroscience.

[4]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Dinsdale,et al.  Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis , 2005, The Journal of cell biology.

[6]  J. Paton,et al.  Targeting specific neuronal populations using adeno‐ and lentiviral vectors: applications for imaging and studies of cell function , 2005, Experimental physiology.

[7]  Á. Almeida,et al.  Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation , 2005, Journal of neurochemistry.

[8]  M. Millan,et al.  Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells , 2004, Experimental Neurology.

[9]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[10]  Y. Itoyama,et al.  Accelerated α-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells , 2004, Brain Research.

[11]  F. Nicoletti,et al.  Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells , 2003, Journal of neurochemistry.

[12]  F. Wouters,et al.  Visualization of molecular activities inside living cells with fluorescent labels. , 2004, International review of cytology.

[13]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[14]  S. Bornstein,et al.  Combinatorial code of growth factors and neuropeptides define neuroendocrine differentiation in PC12 cells , 2003, Experimental Neurology.

[15]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[16]  B. Joseph,et al.  Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. , 2003, Experimental cell research.

[17]  D. Hernandez,et al.  Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. , 2003, Human molecular genetics.

[18]  K. Steece-Collier,et al.  Cellular Models to Study Dopaminergic Injury Responses , 2003, Annals of the New York Academy of Sciences.

[19]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[20]  D. Perl,et al.  Aggresome‐related biogenesis of Lewy bodies , 2002, The European journal of neuroscience.

[21]  P. Brundin,et al.  Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.

[22]  A. Wree,et al.  Dopaminergic differentiation of the Nurr1‐expressing immortalized mesencephalic cell line CSM14.1 in vitro , 2002, Journal of anatomy.

[23]  D. Sulzer,et al.  Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.

[24]  J. Dichgans,et al.  Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. , 2001 .

[25]  R. Anwyl,et al.  Use-Dependent Effects of Amyloidogenic Fragments of β-Amyloid Precursor Protein on Synaptic Plasticity in Rat Hippocampus In Vivo , 2001, The Journal of Neuroscience.

[26]  R. Burke,et al.  Synuclein‐1 is selectively up‐regulated in response to nerve growth factor treatment in PC12 cells , 2001, Journal of neurochemistry.

[27]  J. Haycock,et al.  Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size , 2000, The Journal of Neuroscience.

[28]  R. Davis,et al.  MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). , 1999, Experimental cell research.

[29]  D. Mash,et al.  Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.

[30]  M. Herkenham,et al.  Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum , 1991, Brain Research.

[31]  D. Muller,et al.  A simple method for organotypic cultures of nervous tissue , 1991, Journal of Neuroscience Methods.

[32]  B. Gähwiler,et al.  Organotypic cultures of neural tissue , 1988, Trends in Neurosciences.